Former Organon Exec Will Help Drive Company's Commercialization of
Eligen(R) Technology
CEDAR KNOLLS, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) has announced that Nicholas J. Hart has
joined the company as Vice President of Strategy and Development. In this
capacity, Mr. Hart will be responsible for the planning and commercial
development aspects of the company's Eligen(R) technology, including
Eligen(R) B12.
Mr. Hart comes to Emisphere with over 16 years of commercial experience
in the pharmaceutical industry. In his most recent capacity at Organon,
part of Schering Plough Corporation, he was Leader of the Contraception
Therapy Area and a member of the Corporate Executive Leadership Team. Also
at Organon, he served as Senior Director/Executive Director of Marketing of
the Women's Healthcare Franchise; Director of CNS Marketing, and Associate
Director of Specialty Products. Prior to Organon, Mr. Hart held various
marketing and sales positions with Novartis, Sankyo Parke Davis
Pharmaceuticals, and Bristol-Myers Squibb Company.
After graduating from the United States Military Academy at West Point,
Mr. Hart received an MBA in Finance and International Business from New
York University, Stern School of Business. He also served as a Field
Artillery Officer in the United States Army.
"I am delighted Nick Hart has joined our team at Emisphere to help us
commercialize our Eligen(R) Technology, including Eligen(R) B12," said
Michael V. Novinski, President and Chief Executive Officer of Emisphere.
"He brings a tremendous wealth of experience and a successful track record
of accomplishment in the pharmaceutical industry. He has a demonstrated
skill set both strategically and operationally, and I am confident that
this track record will be continued at Emisphere."
ABOUT EMISPHERE TECHNOLOGIES, INC.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules and
pharmaceutical compounds using its Eligen(R) Technology. Some of these
molecules or compounds can only be given by injection; when combined with
our technology; convenient oral versions may be safe, effective and provide
significant advantages. The benefits of other compounds are limited due to
poor bioavailability, slow on-set of action or variable absorption. In
those cases, use of Emisphere's technology can improve the therapeutic
effectiveness of the compounds. The Eligen(R) Technology can be applied to
the oral route of administration as well other delivery pathways. The Web
site is: http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 13, 2008 and our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2008, filed on August 11, 2008.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com
CONTACT:
Bob Madison, Senior Director Corporate
Communications of Emisphere Technologies, Inc., +1-973-532-8001,
bmadison@emisphere.com; or Adam Friedman of Adam Friedman
Associates for Emisphere Technologies, Inc., +1-212-981-2529,
ext. 18, adam@adam-friedman.com
|
